| EPC467 | Omicron: infection rate and clinical outcomes in Johannesburg, South Africa | E-poster | COVID-19 prevention |
| EPC468 | Nitazoxanide as post exposure prophylaxis (PEP) of COVID-19 household contacts (FH-53 PENTZ) | E-poster | COVID-19 prevention |
| EPC469 | Anti-SARS-CoV-2 antibodies after vaccination in people living with and without HIV | E-poster | COVID-19 prevention |
| EPC470 | 'Why do you want to kill me again? Isn't HIV enough?' Acceptability and factors influencing uptake of COVID-19 vaccines among persons living with HIV in three districts in Uganda | E-poster | COVID-19 prevention |
| EPC471 | Safety and immunogenicity of Sputnik-V, AstraZeneca and Sinopharm vaccines against SARS-CoV-2 in people living with HIV | E-poster | COVID-19 prevention |
| EPC472 | Early receipt of COVID-19 vaccines among people living with HIV: age, knowledge, and trust as determinants | E-poster | COVID-19 prevention |
| EPC473 | Multiple strategies are needed for enrolling individuals in randomized COVID-19 trials. Lessons learned from a home base postexposure trial in Argentina | E-poster | COVID-19 prevention |
| EPC474 | COVID-19 vaccination intention among people who use drugs in France in 2021: results of the international community-based research program EPIC | E-poster | COVID-19 prevention |
| EPC475 | Medical and demographic factors associated with COVID-19 vaccination among people living with HIV (PLWH) in an urban United Kingdom clinic | E-poster | COVID-19 prevention |
| EPC476 | Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SAS CoV-2 infection | E-poster | COVID-19 prevention |